WIPO Re:Search allows organizations to share their intellectual property, compounds, expertise, facilities and know-how royalty-free with qualified researchers working on new solutions for NTDs, malaria and tuberculosis.
Neglected tropical diseases (NTDs), malaria and tuberculosis affect more than one billion people across the globe.
Although recent years have seen the arrival of new R&D models and extra resources, there remains a pressing need to bridge research gaps and bring in knowledge, skills and infrastructure from the private, non-profit, and academic sectors.
The intellectual property (IP), resources, and know-how available via WIPO Re:Search accelerate research into NTDs, malaria, and tuberculosis. In turn this increases the chances of success and reduces costs.
- WIPO Re:Search offers its members access to an extensive range of knowledge assets, compounds, technology, and expertise provided by other private and public sector members. This saves scientists valuable resources and time.
- The Partnership Hub, led by our partner BIO Ventures for Global Health, proactively identifies novel opportunities for collaboration and knowledge-sharing between members.
- WIPO Re:Search facilitates access to private-sector compounds and compound libraries, helping to repurpose drugs.
- It acts as a gateway to a range of development-related tools, including training in IP management.
Through WIPO Re:Search, several of the world’s leading research and development-based pharmaceutical companies and other research and academic institutions are promoting research and development for new drugs, vaccines, and diagnostics for neglected tropical diseases, including tuberculosis and malaria. They are doing this by voluntarily making intellectual property assets and other resources available for licensing.
WIPO Re:Search also provides a searchable, public database of available intellectual property assets and resources. This helps to facilitate new partnerships to support organizations that conduct research on treatments for neglected tropical diseases. The goal is for the database to act as a catalyst to stimulate further sharing of research and ultimately become a living repository of research findings in the field.
It can take up to 13 years for a drug to move from the laboratory, through clinical trials and eventually receive marketing approval. WIPO Re:Search was established in 2011 and has had considerable success in contributing to this process.
Since launch, WIPO Re:Search has tripled its membership, and the Partnership Hub (BVGH) has facilitated 81 research collaborations between members across a wide range of neglected and tropical diseases, mainly for pre-clinical research. It is our belief that the next few years will see outputs of these research collaborations feed into clinical trials – and eventually, approved products.
Research organizations can become a member of WIPO Re:Search by agreeing in writing to our Guiding Principles and stating their intention to become a provider, user or supporter.
Disclaimer: The questions and answers provided on this page serve a purely informative purpose and are not a legal point of reference. They do not necessarily represent the official position of WIPO or its member states.